Zhan-hong Xie
The State Key Laboratory Of Respiratory Disease
Guangzhou, China
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report.
Journal: Human vaccines & immunotherapeutics
Published: August 02, 2023
Allelic Context of EGFR C797X-Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical Outcomes.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: July 03, 2023
Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer.
Journal: Frontiers in oncology
Published: February 28, 2021
Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2-3 After Progression of Second-Line or Later-Line Treatment.
Journal: Cancer management and research
Published: August 24, 2020
Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China.
Journal: The European respiratory journal
Published: March 05, 2020
Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma.
Journal: Frontiers in oncology
Published: January 21, 2020
Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinoma.
Journal: Orphanet journal of rare diseases
Published: December 31, 2019
Efficacy of third-line pemetrexed monotherapy versus pemetrexed combination with bevacizumab in patients with advanced EGFR mutation-positive lung adenocarcinoma.
Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
Published: October 12, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026